巨噬细胞移动抑制因子（MIF）似乎在格林-巴利综合征和实验性变应性神经炎中起关键作用。

Macrophage migration inhibitory factor (MIF) seems crucially involved in Guillain-Barré syndrome and experimental allergic neuritis.

作者信息

Nicoletti Ferdinando, Créange Alain, Orlikowski David, Bolgert Francis, Mangano Katia, Metz Christine, Di Marco Roberto, Al Abed Yousef

机构信息

Department of Biomedical Sciences, School of Medicine, University of Catania, Italy.

出版信息

J Neuroimmunol. 2005 Nov;168(1-2):168-74. doi: 10.1016/j.jneuroim.2005.07.019.

DOI:10.1016/j.jneuroim.2005.07.019

PMID:16171874

Abstract

Macrophage migration inhibitory factor (MIF) is a proinflammatory type 1 cytokine that plays a pathogenic role in several inflammatory and autoimmune diseases. The role of this cytokine in peripheral nerve inflammatory disease has not been evaluated. Therefore, to evaluate the role of macrophage migration inhibitory factor (MIF) in Guillain-Barré syndrome (GBS) and experimental allergic neuritis (EAN), we determined MIF circulating levels in a series of patients with GBS and healthy subjects with ELISA and evaluated the effect of two specific inhibitors of MIF, a neutralizing monoclonal antibody or a chemical inhibitor ISO1 on the course of murine EAN. The data show increased MIF plasma levels in GBS patients as compared to healthy controls (p<0.0001) and a progressive increase of MIF circulating concentration with patient's disability (p<0.0001). Both anti-MIF mAb and ISO1 favorably influenced the course of EAN. Treated mice had a lower cumulative severity score (p=0.001) and reduced disease duration than the control mice (p<0.03). MIF may promote immune reaction in GBS. Therapeutic effects of both anti-MIF mAb and ISO1 in EAN suggest that MIF could be a promising therapeutic target in inflammatory demyelinating peripheral nerve disorders.

摘要

巨噬细胞移动抑制因子（MIF）是一种促炎性1型细胞因子，在多种炎症和自身免疫性疾病中发挥致病作用。该细胞因子在周围神经炎性疾病中的作用尚未得到评估。因此，为了评估巨噬细胞移动抑制因子（MIF）在吉兰-巴雷综合征（GBS）和实验性变应性神经炎（EAN）中的作用，我们采用酶联免疫吸附测定法（ELISA）测定了一系列GBS患者和健康受试者的MIF循环水平，并评估了MIF两种特异性抑制剂（一种中和单克隆抗体或化学抑制剂ISO1）对小鼠EAN病程的影响。数据显示，与健康对照组相比，GBS患者的MIF血浆水平升高（p<0.0001），且MIF循环浓度随患者残疾程度的加重而逐渐升高（p<0.0001）。抗MIF单克隆抗体和ISO1均对EAN病程产生有利影响。治疗组小鼠的累积严重程度评分较低（p=0.001），病程较对照组小鼠缩短（p<0.03）。MIF可能促进GBS中的免疫反应。抗MIF单克隆抗体和ISO1在EAN中的治疗效果表明，MIF可能是炎性脱髓鞘性周围神经疾病中一个有前景的治疗靶点。